Replies to post #195767 on Biotech Values

[DewDiligence]

I’m not sure the Opdivo-vs-Keytruda decision is that easy. In KEYNOTE-001, Keytruda showed an impressive 41% RR in the PD-L1-positive subgroup, defined as described in #msg-117555993.

Of course, a better comparison between the two drugs will be possible when we eventually have OS data for Keytruda in this setting.